SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001104659-22-075811
Filing Date
2022-06-29
Accepted
2022-06-29 16:22:57
Documents
4
Period of Report
2022-08-11

Document Format Files

Seq Description Document Type Size
1 PRE 14A tm2219814-1_pre14a.htm PRE 14A 1631863
2 GRAPHIC lg_nabriva-4c.jpg GRAPHIC 80041
3 GRAPHIC tm2219814d1-px_page01bw.jpg GRAPHIC 650135
4 GRAPHIC tm2219814d1-px_page02bw.jpg GRAPHIC 647932
  Complete submission text file 0001104659-22-075811.txt   3531330
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37558 | Film No.: 221054917
SIC: 2834 Pharmaceutical Preparations